Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

HighVista Strategies initiated a new 13F stake in Cidara Therapeutics (NASDAQ: CDTX), purchasing 70,904 shares valued at $6.79 million — 1.66% of the fund’s reportable U.S. equity AUM as of 9/30/2025; the fund held 148 reportable positions. Cidara shares traded at $105.99 on 2025-11-13 (market cap $2.69B, TTM net loss $184.74M) and have rallied 662.5% over one year after Merck agreed to acquire the biotech for $221.50 cash to secure CD388, a promising influenza prevention candidate; the transaction materially de-risks value for Cidara shareholders but limits near-term upside for new buyers.

Analysis

Market structure: Merck’s announced acquisition of Cidara (CDTX) makes Merck (MRK) the direct beneficiary—it gains a near-term pipeline asset (CD388) and optionality in long‑acting influenza prevention, while CDTX shareholders are likely set to receive $221.50 cash per share. The deal shrinks CDTX public float materially, removing a small-cap biotech from the investable supply and likely compressing biotech small-cap liquidity; competitor pricing power in prophylactic influenza could rise as incumbents (large pharma vaccine franchises) face a new, potentially premium-priced entrant.

Risk assessment: Tail risks include deal collapse (clinical/regulatory surprise, undisclosed liabilities, or hold‑up on antitrust/clearance), which would crater CDTX from deal price; assign low-probability but high-impact loss of ~100% of the spread if the deal breaks before closing. Time horizons: arbitrage returns materialize in days–months (deal close window), clinical/regulatory outcomes and commercialization value realize over 2–5 years. Hidden dependencies: contingent milestones, integration execution, payer reimbursement dynamics, and retention of Cidara scientific team that determine long‑term value beyond the headline price.

Trade implications: Direct arbitrage is primary—buy CDTX only if the market price is >$3–5 below $221.50 and expected close ≤120 days (target annualized return >15%); otherwise avoid expensive small‑cap biotech exposure. For asymmetric exposure to the product’s upside, use MRK 9–18 month call-spreads (small, 1–2% NAV) rather than outright MRK stock to limit carry; consider trimming 20–30% of concentrated small‑cap anti‑infective longs and redeploying into large-cap pharma with M&A optionality. Options: expect IV on CDTX to collapse post-announcement—sell premium selectively on other small biotechs with IV rank >60, capped at 0.25% NAV per trade.

Contrarian angles: Consensus underestimates time-to-revenue—Merck will likely take 2–4 years to generate meaningful global sales from CD388, so near-term MRK upside is limited; the market may overpay for immediate strategic narrative. The arbitrage spread can be a structural opportunity only if the deal is not fully priced; conversely, if the spread is near zero, selling small‑cap volatility or rotating into larger pharma (MRK, PFE) for measured exposure is the better risk/reward. Historical M&A shows integration and payer rates determine realized upside—don’t assume headline price equals commercial success.

Key Decisions for Investors

• Arbitrage CDTX: Establish a 0.5–1.0% NAV long position in CDTX only if market price is ≥$3 below the announced $221.50 deal price and expected close ≤120 days; target gross return >15% annualized and set a hard stop-loss if the spread widens beyond $10 or regulatory news breaches deal terms.
• Merck optionality: Allocate 1–2% NAV to MRK 9–18 month call-spreads (buy 5–10% OTM calls and sell 15–25% OTM calls) to capture upside from CD388 commercialization while capping downside—trim on a 20–25% realized gain or after 12 months.
• Risk reduction in small-cap biotech: Reduce exposure to clinical-stage anti-infective small caps by 20–30% within 30 days; redeploy proceeds into large-cap pharma (e.g., MRK) or cash if CDTX arbitrage spread < $1, because M&A removes float and increases idiosyncratic risk.
• Volatility strategy: If CDTX implied volatility collapses post-announcement, opportunistically sell near-term IV in other single-name small biotechs with IV rank >60 using credit spreads or iron condors sized ≤0.25% NAV per trade, and avoid uncovered naked positions.